4 Aptamer-Based Drug Delivery Systems
111
87. Chen Y, Deng Y, Zhu C, Xiang C (2020) Anti prostate cancer therapy: Aptamer-functionalized,
curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles.
Biomed Pharmacother 127:110181
88. Mir M, Ahmed N, Rehman AU (2017) Recent applications of PLGA based nanostructures in
drug delivery. Colloids Surf B Biointer 159:217–231
89. Xie Z, Su Y, Kim GB, Selvi E, Ma C, Aragon-Sanabria V, Hsieh JT, Dong C, Yang J (2017)
Immune cell-mediated biodegradable theranostic nanoparticles for melanoma targeting and
drug delivery. Small 13(10):1603121
90. Santos AC, Costa D, Ferreira L, Guerra C, Pereira-Silva M, Pereira I, Peixoto D, Ferreira NR,
Veiga F (2020) Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies.
Drug Deliv Transl Res. https://doi.org/10.1007/s13346-020-00778-5
91. Jia Q, Li Z, Guo C, Huang X, Song Y, Zhou N, Wang M, Zhang Z, He L, Du M (2019) A
gamma-cyclodextrin-based metal-organic framework embedded with graphene quantum dots
and modified with PEGMA via SI-ATRP for anticancer drug delivery and therapy. Nanoscale
11(43):20956–20967
92. Jang D, Lee YM, Lee J, Doh J, Kim WJ (2017) Remission of lymphoblastic leukaemia in an
intravascular fluidic environment by pliable drug carrier with a sliding target ligand. Scient
Rep 7:40739. https://doi.org/10.1038/srep40739
93. Li X, Yu Y, Ji Q, Qiu L (2015) Targeted delivery of anticancer drugs by aptamer AS1411
mediated Pluronic F127/cyclodextrin-linked polymer composite micelles. Nanomedicine
11(1):175–184
94. Xu L, Wang SB, Xu C, Han D, Ren XH, Zhang XZ, Cheng SX (2019) Multifunctional albuminbased delivery system generated by programmed assembly for tumor-targeted multimodal
therapy and imaging. ACS Appl Mater Inter 11(42):38385–38394
95. Liu BY, He XY, Zhuo RX, Cheng SX (2018) Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Nanoscale 10(45):21209–21218
96. Lee H, Dellatore SM, Miller WM, Messersmith PB (2007) Mussel-inspired surface chemistry
for multifunctional coatings. Science 318(5849):426–430
97. Liu Y, Ai K, Lu L (2014) Polydopamine and its derivative materials: synthesis and promising
applications in energy, environmental, and biomedical fields. Chem Rev 114(9):5057–5115
98. Tao W, Zeng X, Wu J, Zhu X, Yu X, Zhang X, Zhang J, Liu G, Mei L (2016) Polydopaminebased surface modification of novel nanoparticle-aptamer bioconjugates for in vivo breast
cancer targeting and enhanced therapeutic effects. Theranostics 6(4):470–484
99. Ramezani P, Abnous K, Taghdisi SM, Zahiri M, Ramezani M, Alibolandi M (2020) Targeted
MMP-2 responsive chimeric polymersomes for therapy against colorectal cancer. Colloids
Surf B Biointer 193:111135
100. Khezrian S, Khoee S, Caceres M (2020) Synthesis of combinatorial Janus nanoparticles based
on EpCAM-PEG/PCL for targeted therapy of human colorectal adenocarcinoma. J Biomed
Mater Res A 108(11):2291–2304
101. Xu L, He XY, Liu BY, Xu C, Ai SL, Zhuo RX, Cheng SX (2018) Aptamer-functionalized
albumin-based nanoparticles for targeted drug delivery. Colloids Surf B Biointer 171:24–30
102. Saleh T, Soudi T, Shojaosadati SA (2019) Aptamer functionalized curcumin-loaded human
serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer
cells. Int J Biol Macromol 130:109–116
103. Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A (2016) The toxicology of heparin reversal
with protamine: past, present and future. Expert Opin Drug Metab Toxicol 12(8):897–909
104. Spiridonova VA, Novikova TM, Nikulina DM, Shishkina TA, Golubkina EV, Dyukareva OS,
Trizno NN (2018) Complex formation with protamine prolongs the thrombin-inhibiting effect
of DNA aptamer in vivo. Biochimie 145:158–162
105. Zeng Z, Tung CH, Zu Y (2020) Aptamer-equipped protamine nanomedicine for precision
lymphoma therapy. Cancers (Basel) 12(4):780
106. Liu BY, He XY, Xu C, Ren XH, Zhuo RX, Cheng SX (2019) Peptide and aptamer decorated
delivery system for targeting delivery of Cas9/sgRNA plasmid to mediate antitumor genome
editing. ACS Appl Mater Inter 11(27):23870–23879
111
87. Chen Y, Deng Y, Zhu C, Xiang C (2020) Anti prostate cancer therapy: Aptamer-functionalized,
curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles.
Biomed Pharmacother 127:110181
88. Mir M, Ahmed N, Rehman AU (2017) Recent applications of PLGA based nanostructures in
drug delivery. Colloids Surf B Biointer 159:217–231
89. Xie Z, Su Y, Kim GB, Selvi E, Ma C, Aragon-Sanabria V, Hsieh JT, Dong C, Yang J (2017)
Immune cell-mediated biodegradable theranostic nanoparticles for melanoma targeting and
drug delivery. Small 13(10):1603121
90. Santos AC, Costa D, Ferreira L, Guerra C, Pereira-Silva M, Pereira I, Peixoto D, Ferreira NR,
Veiga F (2020) Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies.
Drug Deliv Transl Res. https://doi.org/10.1007/s13346-020-00778-5
91. Jia Q, Li Z, Guo C, Huang X, Song Y, Zhou N, Wang M, Zhang Z, He L, Du M (2019) A
gamma-cyclodextrin-based metal-organic framework embedded with graphene quantum dots
and modified with PEGMA via SI-ATRP for anticancer drug delivery and therapy. Nanoscale
11(43):20956–20967
92. Jang D, Lee YM, Lee J, Doh J, Kim WJ (2017) Remission of lymphoblastic leukaemia in an
intravascular fluidic environment by pliable drug carrier with a sliding target ligand. Scient
Rep 7:40739. https://doi.org/10.1038/srep40739
93. Li X, Yu Y, Ji Q, Qiu L (2015) Targeted delivery of anticancer drugs by aptamer AS1411
mediated Pluronic F127/cyclodextrin-linked polymer composite micelles. Nanomedicine
11(1):175–184
94. Xu L, Wang SB, Xu C, Han D, Ren XH, Zhang XZ, Cheng SX (2019) Multifunctional albuminbased delivery system generated by programmed assembly for tumor-targeted multimodal
therapy and imaging. ACS Appl Mater Inter 11(42):38385–38394
95. Liu BY, He XY, Zhuo RX, Cheng SX (2018) Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Nanoscale 10(45):21209–21218
96. Lee H, Dellatore SM, Miller WM, Messersmith PB (2007) Mussel-inspired surface chemistry
for multifunctional coatings. Science 318(5849):426–430
97. Liu Y, Ai K, Lu L (2014) Polydopamine and its derivative materials: synthesis and promising
applications in energy, environmental, and biomedical fields. Chem Rev 114(9):5057–5115
98. Tao W, Zeng X, Wu J, Zhu X, Yu X, Zhang X, Zhang J, Liu G, Mei L (2016) Polydopaminebased surface modification of novel nanoparticle-aptamer bioconjugates for in vivo breast
cancer targeting and enhanced therapeutic effects. Theranostics 6(4):470–484
99. Ramezani P, Abnous K, Taghdisi SM, Zahiri M, Ramezani M, Alibolandi M (2020) Targeted
MMP-2 responsive chimeric polymersomes for therapy against colorectal cancer. Colloids
Surf B Biointer 193:111135
100. Khezrian S, Khoee S, Caceres M (2020) Synthesis of combinatorial Janus nanoparticles based
on EpCAM-PEG/PCL for targeted therapy of human colorectal adenocarcinoma. J Biomed
Mater Res A 108(11):2291–2304
101. Xu L, He XY, Liu BY, Xu C, Ai SL, Zhuo RX, Cheng SX (2018) Aptamer-functionalized
albumin-based nanoparticles for targeted drug delivery. Colloids Surf B Biointer 171:24–30
102. Saleh T, Soudi T, Shojaosadati SA (2019) Aptamer functionalized curcumin-loaded human
serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer
cells. Int J Biol Macromol 130:109–116
103. Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A (2016) The toxicology of heparin reversal
with protamine: past, present and future. Expert Opin Drug Metab Toxicol 12(8):897–909
104. Spiridonova VA, Novikova TM, Nikulina DM, Shishkina TA, Golubkina EV, Dyukareva OS,
Trizno NN (2018) Complex formation with protamine prolongs the thrombin-inhibiting effect
of DNA aptamer in vivo. Biochimie 145:158–162
105. Zeng Z, Tung CH, Zu Y (2020) Aptamer-equipped protamine nanomedicine for precision
lymphoma therapy. Cancers (Basel) 12(4):780
106. Liu BY, He XY, Xu C, Ren XH, Zhuo RX, Cheng SX (2019) Peptide and aptamer decorated
delivery system for targeting delivery of Cas9/sgRNA plasmid to mediate antitumor genome
editing. ACS Appl Mater Inter 11(27):23870–23879